TRANSACTIONS GRANTED EARLY TERMINATION BETWEEN: 050895 AND 051995—Continued

Name of acquiring person, name of acquired person, name acquired entity	PMN No.	Dated terminated
Time Warner Inc., Time Warner Inc., The Music Sound Exchange Company	95–1609	05/15/95
Harbour Group Investments III, L.P., Matthew*Warren Group, Inc., Matthew*Warren Group, Inc	95–1625	05/15/95
Carlisle Companies Incorporated, Gordon F. Thomsen, Trail King Industries, Inc	95–1569	05/16/95
Imperial Chemical Industries PLC, Grow Group, Inc., Grow Group, Inc	95–1574	05/16/95
Midwest Resources Inc., McLeod Inc., McLeod Inc	95–1583	05/16/95
IES Industries Inc., McLeod, Inc., McLeod, Inc	95–1584	05/16/95
The Sherwin-Williams Company, Grow Group Inc., Grow Group Inc	95–1618	05/16/95
Newell Co., Marshall S. Cogan, CHF Industries, Inc	95–1605	05/17/95
Illinois Tool Works Inc., Foamseal Inc., Foamseal Inc	95–1532	05/18/95
ConAgra, Inc., The Quaker Oats Company, Stokely-Van Camp, Inc	95–1571	05/18/95
Baptist Health Systems of South Florida, Inc., South Miami Health System, Inc., South Miami Hospital, Inc., SMH Homestead Hospital	95–1575	05/18/95
Charterhouse Equity Partners II, L.P., Masada Cable Partners, L.P., Masada Cable Partners, L.P.	95–1596	05/18/95
Coram Healthcare Corporation, Lincare Holdings, Inc., Lincare Holdings, Inc	95–1626	05/18/95

FOR FURTHER INFORMATION CONTACT: Sandra M. Peay or Renee A. Horton, Contact Representatives, Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room 303, Washington, D.C. 20580, (202) 326–3100.

By Direction of The Commission.

Donald S. Clark,

Secretary.

[FR Doc. 95–13362 Filed 5–31–95; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration on Aging

White House Conference on Aging

AGENCY: White House Conference on Aging, AoA, HHS.

ACTION: Notice of meeting.

SUMMARY: Notice is hereby given, pursuant to Title II of the Older Americans Act Amendments of 1987, Pub. L. 100–175 as amended by Pub. L. 102–375, and Pub. L. 103–171, that the 1995 White House Conference on Aging Advisory Committee will hold a meeting on Wednesday, June 14, 1995, in Washington, DC. The general meeting will begin at 10:00 a.m. and end at approximately 12:00 noon. More specific information on the location for the meeting can be obtained by calling the telephone number given below.

The general meeting of the Committee shall be open to the public. The proposed agenda includes preparation of the proposed report of the Conference which is to be transmitted to the chief executive officers of the States by August 3, 1995.

Records shall be kept of all Committee proceedings and shall be available for public inspection at 501 School Street SW., 8th Floor, Washington, DC 20024.

FOR FURTHER INFORMATION CONTACT: White House Conference on Aging, 501 School Street SW., 8th Floor, Washington, DC 20024; telephone (202) 245–7116.

Dated: May 25, 1995.

Fernando M. Torres-Gil,

Assistant Secretary for Aging.

[FR Doc. 95–13291 Filed 5–31–95; 8:45 am]

BILLING CODE 4130–02–M

Food and Drug Administration

[Docket No. 95N–0137]

Drug Export; Antibody to Hepatitis B Surface Antigen (Human) Ortho™ Antibody to HBsAg Elisa Confirmatory Test

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Ortho Diagnostic Systems, Inc., has filed an application requesting approval for the export of the human biological product Antibody to Hepatitis B Surface Antigen (human) ORTHO™ Antibody to HBsAg ELISA Confirmatory Test to Austria, Belgium, Canada, Denmark, Federal Republic of Germany, Finland, France, Iceland, Ireland, Italy, Japan, Luxembourg, The Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, and The United Kingdom.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human biological products under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: Cathy Conn, Center for Biologics Evaluation and Research (HFM–610), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–594–2006.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of human biological products that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the **Federal Register** within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that Ortho Diagnostic Systems, Inc., 1001 US Hwy. 202, Raritan, NJ 08869, has filed an application requesting approval for the export of the human biological product Antibody to Hepatitis B Surface Antigen (human) ORTHO™ Antibody to HBsAg ELISA Confirmatory Test to Austria, Belgium, Canada, Denmark, Federal Republic of Germany, Finland, France, Iceland, Ireland, Italy, Japan, Luxembourg, The Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, and The United Kingdom. The Antibody to Hepatitis B Surface Antigen (human)

ORTHO™ Antibody to HBsAg ELISA Confirmatory Test is a third generation assay to be used to confirm the presence of Hepatitis B Surface Antigen (HBsAg) in specimens found repeatedly reactive in ORTHO™ Antibody to HBsAg ELISA Test System 3. The application was received and filed in the Center for Biologics Evaluation and Research on May 4, 1995, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by June 12, 1995, and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Biologics Evaluation and Research (21 CFR 5.44).

Dated: May 9, 1995.

James C. Simmons,

Acting Director, Office of Compliance, Center for Biologics Evaluation and Research.

[FR Doc. 95–13295 Filed 5–31–95; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 95N–0143]

Drug Export; PEG-L-Asparaginase

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Enzon, Inc., has filed an application requesting approval for the export of the human biological product PEG-L-asparaginase to The Federal Republic of Germany.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human biological products under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: Cathy E. Conn, Center for Biologics Evaluation and Research (HFM–610), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–594–2006.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of human biological products that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the **Federal Register** within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that Enzon, Inc., 40 Kingsbridge Rd., Piscataway, NJ 08854, has filed an application requesting approval for the export of the human biological product PEG-L-asparaginase to The Federal Republic of Germany. PEG-L-asparaginase is an antineoplastic combination therapy for reinduction in the case of acute lymphatic leukemia (ALL) in childhood and adulthood in the case of patients with known hypersensitivity to ''native'' L-asparaginase. The application was received and filed in the Center for Biologics Evaluation and Research on May 15, 1995, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by June 12, 1995 and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Biologics Evaluation and Research (21 CFR 5.44).

Dated: May 18, 1995.

James C. Simmons,

Acting Director, Office of Compliance, Center for Biologics Evaluation and Research.

[FR Doc. 95–13411 Filed 5–31–95; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 95N–0142]

Drug Export; Caverject Sterile Powder (Alprostadil for Injection) 20 Micrograms per Milliliter (μG/mL) Vials

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that The Upjohn Co. has filed an application requesting approval for the export of the human drug CAVERJECT Sterile Powder (Alprostadil for Injection) 20μg/mL vials to Sweden via Belgium.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human drugs under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: James E. Hamilton, Center for Drug Evaluation and Research (HFD–310), Food and Drug Administration, 7520 Standish Pl., Rockville, MD 20857, 301–594–3150.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of drugs that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the **Federal Register** within 10 days of the filing of an application for export to facilitate public